Afsaneh Barzi

6.6k total citations · 1 hit paper
173 papers, 5.0k citations indexed

About

Afsaneh Barzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Afsaneh Barzi has authored 173 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 45 papers in Pathology and Forensic Medicine. Recurrent topics in Afsaneh Barzi's work include Colorectal Cancer Treatments and Studies (76 papers), Genetic factors in colorectal cancer (39 papers) and Gastric Cancer Management and Outcomes (32 papers). Afsaneh Barzi is often cited by papers focused on Colorectal Cancer Treatments and Studies (76 papers), Genetic factors in colorectal cancer (39 papers) and Gastric Cancer Management and Outcomes (32 papers). Afsaneh Barzi collaborates with scholars based in United States, Japan and Italy. Afsaneh Barzi's co-authors include Stacey A. Fedewa, Rebecca L. Siegel, Ahmedin Jemal, Dennis J. Ahnen, Kimberly D. Miller, Reinier G.S. Meester, Heinz‐Josef Lenz, Sarmad Sadeghi, Annika Lenz and Melissa J. LaBonte and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Afsaneh Barzi

159 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colorectal cancer statistics, 2017

2017 3.1k citations Afsaneh Barzi et al. profile →

Peers

Countries citing papers authored by Afsaneh Barzi

Since Specialization

Citations

This map shows the geographic impact of Afsaneh Barzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Afsaneh Barzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Afsaneh Barzi more than expected).

Fields of papers citing papers by Afsaneh Barzi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Afsaneh Barzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Afsaneh Barzi. The network helps show where Afsaneh Barzi may publish in the future.

Co-authorship network of co-authors of Afsaneh Barzi

This figure shows the co-authorship network connecting the top 25 collaborators of Afsaneh Barzi. A scholar is included among the top collaborators of Afsaneh Barzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Afsaneh Barzi. Afsaneh Barzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequencing considerations in the third-line treatment of metastatic colorectal cancer 2024 ·The American Journal of Managed Care ·Afsaneh Barzi	2
2	Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases 2024 ·Future Oncology ·Daneng Li, Christiana Crook, Vincent Chung, Gagandeep Brar, Marwan Fakih, Afsaneh Barzi, Laleh G. Melstrom, Gagandeep Singh, Yuman Fong, Paul Frankel, Mustafa Raoof	0
3	Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial 2024 ·Journal of Clinical Oncology ·Daniel H. Ahn, Maya Ridinger, Timothy Lewis Cannon, (unknown), Jason S. Starr, Joleen M. Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A. Subramanian, (unknown), Roy Kim, (unknown), Peter J.P. Croucher, Tod Smeal, Fairooz F. Kabbinavar, Heinz‐Josef Lenz	11
4	Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis 2024 ·Clinical Colorectal Cancer ·Zdravko P. Vassilev, Xiaozhou Fan, Julie Xu, (unknown), Afsaneh Barzi	2
5	Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data 2023 ·Journal of Personalized Medicine ·Afsaneh Barzi, (unknown), (unknown), Howard West, David T. Wong, Carol Wright, Nitya Nathwani, (unknown), Vincent Chung, Douglas A. Rubinson, (unknown)	1
6	Patient Care Satisfaction and Emergency Room Utilization among Young Adult Colorectal Cancer Survivors during the SARS-CoV-2 Pandemic: Lessons Learned 2023 ·Journal of Clinical Medicine ·(unknown), Kimberly A. Miller, (unknown), David R. Freyer, Joel Milam, Heinz‐Josef Lenz, Afsaneh Barzi	0
7	Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age-stratified analysis. 2023 ·Journal of Clinical Oncology ·Zdravko P. Vassilev, (unknown), (unknown), Julie Xu, Afsaneh Barzi	0
8	A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01) 2022 ·Cancer Research Communications ·Aaron J. Scott, Atrayee Basu Mallick, Efrat Dotan, Steven J. Cohen, Philip J. Gold, Howard S. Höchster, Somasundaram Subramaniam, Afsaneh Barzi, George S. Watts, Patrick J. Blatchford, Wells A. Messersmith	14
9	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates 2022 ·The Oncologist ·(unknown), (unknown), (unknown), (unknown), Afsaneh Barzi, David R. Freyer, Joel Milam, Heinz‐Josef Lenz, Kimberly A. Miller	15
10	P-156 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress 2022 ·Annals of Oncology ·Josep Tabernero, John H. Strickler, Yoshiaki Nakamura, (unknown), Yelena Y. Janjigian, Afsaneh Barzi, Tanios Bekaii‐Saab, (unknown), Takashi Yoshino, Salvatore Siena, (unknown), (unknown), Diqiong Xie, (unknown)	2
11	Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors 2021 ·Cancers ·Kimberly A. Miller, (unknown), (unknown), Zhen Weng, David R. Freyer, (unknown), (unknown), Heinz‐Josef Lenz, Joel Milam, (unknown), Afsaneh Barzi	16
12	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial 2021 ·The Oncologist ·Aminah Jatoi, Fang‐Shu Ou, Daniel H. Ahn, Tyler Zemla, Jennifer Le‐Rademacher, Patrick M. Boland, Kristen K. Ciombor, Nisha L. Jacobs, Boris Pasche, James M. Cleary, Jeannine S. McCune, Katrina S. Pedersen, Afsaneh Barzi, E. Gabriela Chiorean, Erica N. Heying, Heinz‐Josef Lenz, Jeff A. Sloan, Axel Grothey, Mario E. Lacouture, Tanios Bekaii‐Saab	5
13	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors 2021 ·Journal of Adolescent and Young Adult Oncology ·Kimberly A. Miller, (unknown), (unknown), (unknown), Zhen Weng, (unknown), (unknown), David R. Freyer, Afsaneh Barzi, Heinz‐Josef Lenz	9
14	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer 2020 ·Journal of Adolescent and Young Adult Oncology ·Afsaneh Barzi, Caroline Weipert, Carin R. Espenschied, Heinz‐Josef Lenz	1
15	436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer 2020 ·Annals of Oncology ·Daniel H. Ahn, Mark G. Erlander, Maya Ridinger, Errin Samuëlsz, Afsaneh Barzi, Tanios Bekaii‐Saab, Heinz‐Josef Lenz	5
16	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States 2018 ·Clinical Colorectal Cancer ·(unknown), Joel W. Hay, Afsaneh Barzi	36
17	Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Eunjung Lee, Lihua Liu, Juanjuan Zhang, Mariana C. Stern, Afsaneh Barzi, Amie E. Hwang, (unknown), Ann S. Hamilton, Anna H. Wu, Dennis Deapen	28
18	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach 2015 ·Molecular Cancer Therapeutics ·Yan Ning, Diana L. Hanna, Wu Zhang, Angela Mendez, Dongyun Yang, Rita El‐Khoueiry, Satoshi Matsusaka, Yu Sunakawa, Stefan Stremitzer, (unknown), Satoshi Okazaki, Martin D. Berger, Afsaneh Barzi, Heinz‐Josef Lenz	22
19	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States 2013 ·Molecular Cancer Therapeutics ·Takeru Wakatsuki, Melissa J. LaBonte, Pierre Bohanes, Wu Zhang, Dongyun Yang, Mizutomo Azuma, Afsaneh Barzi, Yan Ning, Fotios Loupakis, (unknown), (unknown), Sebastian Stintzing, Rita El‐Khoueiry, Wasaburo Koizumi, Masahiko Watanabe, Manish A. Shah, Justin Stebbing, Georgios Giamas, Heinz‐Josef Lenz	18
20	Correlation between lowered PgE2 levels and alkaline reflux gastritis in patients subjected to Billroth II. Pylorogastrectomy: possible improvement with sulglycotide. 1987 ·PubMed ·Piero Chirletti, Afsaneh Barzi, Antonio Bolognese, Paolo Sammartino, (unknown), A. Cenedese, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact